Bank of America’s Eledon Pharmaceuticals ELDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.68M | Buy |
869,544
+809,446
| +1,347% | +$1.91M | ﹤0.01% | 3913 |
|
|
2025
Q4 | $90.7K | Buy |
60,098
+14,869
| +33% | +$35.3K | ﹤0.01% | 5657 |
|
|
2025
Q3 | $117K | Buy |
45,229
+19,862
| +78% | +$58.1K | ﹤0.01% | 6529 |
|
|
2025
Q2 | $68.7K | Buy |
25,367
+18,355
| +262% | +$55.1K | ﹤0.01% | 6687 |
|
|
2025
Q1 | $23.8K | Sell |
7,012
-88,130
| -93% | -$363K | ﹤0.01% | 6922 |
|
|
2024
Q4 | $392K | Buy |
95,142
+88,326
| +1,296% | +$348K | ﹤0.01% | 5723 |
|
|
2024
Q3 | $17K | Sell |
6,816
-2
| -0% | -$5 | ﹤0.01% | 6781 |
|
|
2024
Q2 | $18K | Buy |
+6,818
| New | +$16.3K | ﹤0.01% | 6760 |
|
|
2024
Q1 | – | Sell |
-15
| Closed | -$27 | – | 7850 |
|
|
2023
Q4 | $27 | Buy |
+15
| New | +$21 | ﹤0.01% | 7603 |
|
|
2023
Q1 | – | Sell |
-14
| Closed | -$32 | – | 7917 |
|
|
2022
Q4 | $32 | Buy |
+14
| New | +$35 | ﹤0.01% | 7887 |
|
|
2022
Q1 | – | Sell |
-27
| Closed | – | – | 8377 |
|
|
2021
Q4 | $0 | Sell |
27
-184
| -87% | -$931 | ﹤0.01% | 8321 |
|
|
2021
Q3 | $1K | Buy |
211
+70
| +50% | +$489 | ﹤0.01% | 7970 |
|
|
2021
Q2 | $1K | Buy |
+141
| New | +$1.33K | ﹤0.01% | 7604 |
|
|
2021
Q1 | – | Sell |
-1,020
| Closed | -$16K | – | 7500 |
|
|
2020
Q4 | $16K | Sell |
1,020
-813
| -44% | -$15.5K | ﹤0.01% | 6630 |
|
|
2020
Q3 | $32K | Buy |
+1,833
| New | +$18.1K | ﹤0.01% | 6170 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6939 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 7156 |
|
|
2019
Q2 | – | Sell |
-25
| Closed | -$2K | – | 7241 |
|
|
2019
Q1 | $2K | Buy |
+25
| New | +$1.66K | ﹤0.01% | 6902 |
|
|
2018
Q4 | – | Sell |
-31
| Closed | -$3K | – | 7170 |
|
|
2018
Q3 | $3K | Buy |
+31
| New | +$3.16K | ﹤0.01% | 6940 |
|
|
2018
Q2 | – | Sell |
-4
| Closed | -$413 | – | 7133 |
|
|
2018
Q1 | $0 | Buy |
+4
| New | +$295 | ﹤0.01% | 7152 |
|
|
2017
Q3 | – | Sell |
-25
| Closed | -$3K | – | 7102 |
|
|
2017
Q2 | $3K | Buy |
25
+14
| +127% | +$1.43K | ﹤0.01% | 6674 |
|
|
2017
Q1 | $1K | Sell |
11
-5
| -31% | -$735 | ﹤0.01% | 6848 |
|
|
2016
Q4 | $2K | Buy |
16
+1
| +7% | +$192 | ﹤0.01% | 6839 |
|
|
2016
Q3 | $4K | Sell |
15
-81
| -84% | -$29.6K | ﹤0.01% | 6671 |
|
|
2016
Q2 | $85K | Sell |
96
-187
| -66% | -$206K | ﹤0.01% | 5601 |
|
|
2016
Q1 | $257K | Buy |
283
+191
| +208% | +$187K | ﹤0.01% | 5002 |
|
|
2015
Q4 | $129K | Buy |
92
+79
| +608% | +$138K | ﹤0.01% | 5613 |
|
|
2015
Q3 | $22K | Buy |
+13
| New | +$26.8K | ﹤0.01% | 6280 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 7119 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6800 |
|
Other funds holding ELDN
BI
DCM
VCM
ZP
SFM
CCM
BOCH
Bank of America's ELDN Position: Q1 2026 in Review
Bank of America increased its Eledon Pharmaceuticals (ELDN) stake by 1,347% in Q1 2026, buying an estimated $1.91M and bringing the position to 869,544 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3913.
Bank of America first reported a position in ELDN in Q3 2015 and has held it in 26 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.
- Bank of America held 869,544 shares of Eledon Pharmaceuticals worth $2.68M as of Q1 2026.
- Bank of America bought 809,446 Eledon Pharmaceuticals shares in Q1 2026, an estimated $1.91M.
- Eledon Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3913 holding.
- Bank of America first reported a position in Eledon Pharmaceuticals in Q3 2015 and has held it in 26 quarters since.
- 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.